Skip to content

BPL1-Enriched Whey Protein Supplementation Modulates Body Composition and Metabolic Profiles in Overweight and Obese Adults

BPL1-Enriched Whey Protein Supplementation Modulates Body Composition and Metabolic Profiles in Overweight and Obese Adults

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107921
Enrollment
Unknown
Registered
2025-08-21
Start date
2025-08-31
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obese

Interventions

Placebo group:Participants will follow a calorie-restricted diet and perform resistance training four days per week, while consuming one sachet of placebo within 30 minutes prior to exercise, for a to
Protein supplement group:Participants will follow a calorie-restricted diet and perform resistance training four days per week, while consuming one sachet of protein supplements within 30 minutes prio
Functional ingredient supplement group:Participants will follow a calorie-restricted diet and perform resistance training four days per week, while consuming one sachet of active supplements within 30

Sponsors

Second Affiliated Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adults aged 25–45 years, male or female; 2. Body Mass Index (BMI) between 24.0 and 29.9 kg/m^2; 3. Engaged in leisure-time physical activity but not in structured resistance training for at least 12 months; 4. Habitual protein intake < ~1.6 g/kg body weight per day; 5. Willing and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1. Current smoking, excessive alcohol use, or other unhealthy lifestyle habits (e.g., chronic sleep deprivation); 2. Use of anabolic steroids or protein-synthesis–enhancing supplements (e.g., HMB, creatine, BCAAs) within the past year; 3. Uncontrolled metabolic or cardiovascular disorders, including heart disease, hypertension, diabetes, thyroid dysfunction, or hypogonadism; 4. Clinically significant hepatic, renal, musculoskeletal, autoimmune, neurological, or psychiatric disorders; 5. Gastrointestinal diseases impairing nutrient digestion or absorption (e.g., chronic diarrhea, severe inflammation, active peptic ulcer, or history of major GI surgery); 6. Known allergy to study product ingredients or congenital metabolic disorders; 7. Pregnancy, lactation, or significant gynecological issues (e.g., severe dysmenorrhea, marked menstrual irregularity); 8. Any other condition considered by the investigators to render the participant unsuitable for the study.

Design outcomes

Primary

MeasureTime frame
Fasting blood glucose;Glycated hemoglobin ;Glycated albumin;Fasting insulin;Glucagon-like peptide-1;Triglycerides ;Total cholesterol;Body weight;Body fat percentage;Lean body mass;

Countries

China

Contacts

Public ContactPianhong Zhang

Department of Nutrition, Second Affiliated Hospital of Zhejiang University School of Medicine

zph713@163.com+86 137 5711 9193

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026